vs

Side-by-side financial comparison of Marqeta, Inc. (MQ) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $172.1M, roughly 1.2× Marqeta, Inc.). On growth, Marqeta, Inc. posted the faster year-over-year revenue change (26.7% vs 25.9%). Marqeta, Inc. produced more free cash flow last quarter ($53.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 20.8%).

Marqeta, Inc. operates a cloud-native open API platform for modern card issuing and digital payment processing. Its solutions empower fintech startups, large retailers, and enterprise clients to launch customized physical and virtual payment cards, as well as embedded finance products across global consumer and commercial markets.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MQ vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.2× larger
RARE
$207.3M
$172.1M
MQ
Growing faster (revenue YoY)
MQ
MQ
+0.9% gap
MQ
26.7%
25.9%
RARE
More free cash flow
MQ
MQ
$153.9M more FCF
MQ
$53.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
20.8%
MQ

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MQ
MQ
RARE
RARE
Revenue
$172.1M
$207.3M
Net Profit
$-128.6M
Gross Margin
69.7%
Operating Margin
-4.8%
-54.7%
Net Margin
-62.0%
Revenue YoY
26.7%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MQ
MQ
RARE
RARE
Q4 25
$172.1M
$207.3M
Q3 25
$163.3M
$159.9M
Q2 25
$150.4M
$166.5M
Q1 25
$139.1M
$139.3M
Q4 24
$135.8M
$164.6M
Q3 24
$128.0M
$139.5M
Q2 24
$125.3M
$147.0M
Q1 24
$118.0M
$108.8M
Net Profit
MQ
MQ
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-3.6M
$-180.4M
Q2 25
$-647.0K
$-115.0M
Q1 25
$-8.3M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-28.6M
$-133.5M
Q2 24
$119.1M
$-131.6M
Q1 24
$-36.1M
$-170.7M
Gross Margin
MQ
MQ
RARE
RARE
Q4 25
69.7%
Q3 25
70.1%
Q2 25
69.2%
Q1 25
71.0%
Q4 24
72.3%
Q3 24
70.4%
Q2 24
63.3%
Q1 24
71.3%
Operating Margin
MQ
MQ
RARE
RARE
Q4 25
-4.8%
-54.7%
Q3 25
-6.4%
-106.9%
Q2 25
-6.1%
-64.8%
Q1 25
-13.3%
-102.6%
Q4 24
-27.6%
-74.3%
Q3 24
-33.0%
-94.6%
Q2 24
83.9%
-79.1%
Q1 24
-42.3%
-151.9%
Net Margin
MQ
MQ
RARE
RARE
Q4 25
-62.0%
Q3 25
-2.2%
-112.8%
Q2 25
-0.4%
-69.0%
Q1 25
-5.9%
-108.5%
Q4 24
-80.9%
Q3 24
-22.4%
-95.7%
Q2 24
95.1%
-89.5%
Q1 24
-30.6%
-156.8%
EPS (diluted)
MQ
MQ
RARE
RARE
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MQ
MQ
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$709.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$762.0M
$-80.0M
Total Assets
$1.5B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MQ
MQ
RARE
RARE
Q4 25
$709.4M
$421.0M
Q3 25
$747.2M
$202.5M
Q2 25
$732.7M
$176.3M
Q1 25
$830.9M
$127.1M
Q4 24
$923.0M
$174.0M
Q3 24
$886.4M
$150.6M
Q2 24
$924.7M
$480.7M
Q1 24
$970.4M
$112.3M
Stockholders' Equity
MQ
MQ
RARE
RARE
Q4 25
$762.0M
$-80.0M
Q3 25
$839.2M
$9.2M
Q2 25
$843.4M
$151.3M
Q1 25
$987.3M
$144.2M
Q4 24
$1.1B
$255.0M
Q3 24
$1.1B
$346.8M
Q2 24
$1.1B
$432.4M
Q1 24
$1.2B
$140.3M
Total Assets
MQ
MQ
RARE
RARE
Q4 25
$1.5B
$1.5B
Q3 25
$1.5B
$1.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.3B
$1.3B
Q4 24
$1.5B
$1.5B
Q3 24
$1.4B
$1.5B
Q2 24
$1.5B
$1.6B
Q1 24
$1.6B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MQ
MQ
RARE
RARE
Operating Cash FlowLast quarter
$53.3M
$-99.8M
Free Cash FlowOCF − Capex
$53.2M
$-100.8M
FCF MarginFCF / Revenue
30.9%
-48.6%
Capex IntensityCapex / Revenue
0.1%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$160.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MQ
MQ
RARE
RARE
Q4 25
$53.3M
$-99.8M
Q3 25
$86.8M
$-91.4M
Q2 25
$12.5M
$-108.3M
Q1 25
$10.0M
$-166.5M
Q4 24
$24.8M
$-79.3M
Q3 24
$7.3M
$-67.0M
Q2 24
$25.7M
$-77.0M
Q1 24
$426.0K
$-190.7M
Free Cash Flow
MQ
MQ
RARE
RARE
Q4 25
$53.2M
$-100.8M
Q3 25
$86.4M
$-92.7M
Q2 25
$12.2M
$-110.7M
Q1 25
$8.7M
$-167.8M
Q4 24
$24.7M
$-79.5M
Q3 24
$7.1M
$-68.6M
Q2 24
$24.7M
$-79.0M
Q1 24
$-765.0K
$-193.9M
FCF Margin
MQ
MQ
RARE
RARE
Q4 25
30.9%
-48.6%
Q3 25
52.9%
-58.0%
Q2 25
8.1%
-66.5%
Q1 25
6.3%
-120.5%
Q4 24
18.2%
-48.3%
Q3 24
5.5%
-49.2%
Q2 24
19.7%
-53.7%
Q1 24
-0.6%
-178.2%
Capex Intensity
MQ
MQ
RARE
RARE
Q4 25
0.1%
0.5%
Q3 25
0.2%
0.8%
Q2 25
0.2%
1.5%
Q1 25
0.9%
1.0%
Q4 24
0.0%
0.1%
Q3 24
0.1%
1.2%
Q2 24
0.8%
1.4%
Q1 24
1.0%
3.0%
Cash Conversion
MQ
MQ
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MQ
MQ

Platform Service Revenue Net$163.4M95%
Other Services Revenue$8.8M5%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons